Grail shares surge ahead of FDA meeting on cancer-detecting blood test
Grail's stock rose more than 30% after briefing documents were released before a Food and Drug Administration panel meeting on its blood test for early cancer detection.
Grail Inc.'s shares jumped over 30% on Monday following the release of briefing documents that will be reviewed at a Food and Drug Administration advisory committee meeting scheduled for Wednesday. The documents pertain to the company's blood test designed to detect multiple types of cancer at early stages. Analysts noted that the filing could influence the regulator's decision on whether to grant market approval for the test, which has been under development for several years. Investors have responded positively to the prospect of a new diagnostic tool that could expand early-cancer screening options.
"The briefing materials provide a comprehensive overview of the test's clinical performance and potential impact on patient outcomes," a company spokesperson said. The FDA meeting will allow independent experts to evaluate the test's safety and efficacy before any final regulatory action is taken.